Hellenic registry of patients with home mechanical ventilation (HR-HMV): profiling sleep Apnea-Hypopnea syndrome patients across Greece.

BACKGROUND: Chronic respiratory conditions are a prominent public health issue and thus, building a patient registry might facilitate both policy decision making and improvement of clinical management processes. Hellenic Registry of patients with Home Mechanical Ventilation (HR-HMV) was initiated in 2017 and a web-based platform is used to support patient data collection. Eighteen hospital departments (including sleep labs) across Greece participate in this initiative, focusing on recording data for both children and adult patients supported by mechanical ventilation at home, including patients with Sleep Apnea-Hypopnea Syndrome (SAHS) under Positive Airway Pressure (PAP) therapy. METHODS: The HR-HMV initiative ultimately aims to provide a database for evidence-based care and policy making in this specific domain. To this end, a web information system was developed and data were manually collected by clinics and hospital departments. Legal and privacy issues (such as General Data Protection Rule compliance and technical information security measures) have been considered while designing the web application. Based on the collected data, an exploratory statistical report of SAHS patients in Greece is presented. RESULTS: Eleven out of the eighteen participating clinics and hospital departments have contributed with data by the time of the current study. More than 5000 adult and children patient records have been collected so far, the vast majority of which (i.e., 4900 patients) diagnosed with SAHS. CONCLUSION: The development and maintenance of patient registries is a valuable tool for policy decision making, observational/epidemiological research and beyond (e.g., health technology assessment procedures). However, as all data collection and processing approaches, registries are also related with potential biases. Along these lines, strengths and limitations must be considered when interpreting the collected data, and continuous validation of the collected clinical data per se should be emphasized. Especially for Greece, where the lack of national registries is eminent, we argue that HR-HMV could be a useful tool for the development and the update of related policies regarding the healthcare services for patients with home mechanical ventilation support and SAHS patients, which could be useful for related initiatives at a European level as well.

Change in CF care during COVID-19 pandemic: Single-center experience in a middle-income setting.

INTRODUCTION: The coronavirus 2019 (COVID-19) pandemic has demanded care changes for patients with chronic disease. Patients with cystic fibrosis (CF) are considered at higher risk of developing severe manifestations in the case of SARS-CoV-2 infection, and a need for new ways of safer care delivery has been required to avoid transmission. OBJECTIVES: To assess the impact of the lockdown during the first wave of the COVID-19 pandemic and remote monitoring on patient's health status and daily maintenance therapy in a middle-income resource setting. METHODS: During the first wave of the pandemic period, we changed from regular clinic visits to telephone visit calls to monitor our patients' health condition and adherence to physiotherapy and physical exercise. RESULTS: A total of 120 patients or their caregivers have been contacted by telephone call visits over 10 weeks. During this period, 38 patients (28.33%) were identified to have pulmonary exacerbation; 89.5% were prescribed oral antibiotics, 3% were hospitalized to get iv antibiotics, and 8% of the patients presented other CF complications. Most of the patients did not change the frequency of the daily physiotherapy. Moreover, 71% of the patients who performed regular physical exercise changed the frequency and the type of exercise during the quarantine period. Interestingly, mean forced expiratory volume in 1 s and body weight increased significantly and after the lockdown period. CONCLUSIONS: During the COVID-19 pandemic, the implementation of telephone contact processes aiming for CF patients' appropriate care is of great importance. Further studies are needed to evaluate patient outcomes when transitioning from face-to-face clinics to telemedicine clinics.

Evaluation of a Decision Support System for Obstructive Sleep Apnea with Nonlinear Analysis of Respiratory Signals.

INTRODUCTION: Obstructive Sleep Apnea (OSA) is a common sleep disorder requiring the time/money consuming polysomnography for diagnosis. Alternative methods for initial evaluation are sought. Our aim was the prediction of Apnea-Hypopnea Index (AHI) in patients potentially suffering from OSA based on nonlinear analysis of respiratory biosignals during sleep, a method that is related to the pathophysiology of the disorder. MATERIALS AND METHODS: Patients referred to a Sleep Unit (135) underwent full polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) extracted from two biosignals (airflow from a nasal cannula, thoracic movement) and one linear derived from Oxygen saturation provided input to a data mining application with contemporary classification algorithms for the creation of predictive models for AHI. RESULTS: A linear regression model presented a correlation coefficient of 0.77 in predicting AHI. With a cutoff value of AHI = 8, the sensitivity and specificity were 93% and 71.4% in discrimination between patients and normal subjects. The decision tree for the discrimination between patients and normal had sensitivity and specificity of 91% and 60%, respectively. Certain obtained nonlinear values correlated significantly with commonly accepted physiological parameters of people suffering from OSA. DISCUSSION: We developed a predictive model for the presence/severity of OSA using a simple linear equation and additional decision trees with nonlinear features extracted from 3 respiratory recordings. The accuracy of the methodology is high and the findings provide insight to the underlying pathophysiology of the syndrome. CONCLUSIONS: Reliable predictions of OSA are possible using linear and nonlinear indices from only 3 respiratory signals during sleep. The proposed models could lead to a better study of the pathophysiology of OSA and facilitate initial evaluation/follow up of suspected patients OSA utilizing a practical low cost methodology. TRIAL REGISTRATION: ClinicalTrials.gov NCT01161381.

Successful management of drug-induced hypercapnic acidosis with naloxone and noninvasive positive pressure ventilation.

A 74-year-old man was referred to our hospital due to deteriorating level of consciousness and desaturation. His Glasgow Coma Scale was 6, and his pupils were constricted but responded to light. Chest radiograph was negative for significant findings. Arterial blood gas evaluation on supplemental oxygen revealed severe acute on chronic respiratory acidosis: pH 7.15; PCO2, 133 mm Hg; PO2,64 mm Hg; and HCO3, 31 mmol/L. He regained full consciousness (Glasgow Coma Scale, 15) after receiving a 0.4 mg dose of naloxone, but because of persistent severe respiratory acidosis (pH 7.21; PCO2, 105 mm Hg), he was immediately commenced on noninvasive positive pressure ventilation (NIV) displaying a remarkable improvement in arterial blood gas values within the next few hours. However, in the days that followed, he remained dependent on NIV, and he was finally discharged on a home mechanical ventilation prescription. In cases of drug-induced respiratory depression, NIV should be regarded as an acceptable treatment, as it can provide ventilatory support without the increased risks associated with invasive mechanical ventilation.

Serum Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor Binding Protein-3 in Obstructive Sleep Apnea Patients: Effect of Continuous Positive Airway Pressure Treatment.

BACKGROUND AND AIM: Hypoxia, a major feature of obstructive sleep apnea (OSA), modifies Vascular Endothelial Growth Factor (VEGF) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) levels, which contribute to atherogenesis and occurrence of cardiovascular (CV) events. We assessed and compared serum levels of VEGF and IGFBP-3 in newly diagnosed OSA patients and controls, to explore associations with anthropometric and sleep parameters and to study the effect of continuous positive airway pressure (CPAP) treatment on these levels. MATERIALS AND METHODS: Serum levels of VEGF and IGFBP-3 were measured in 65 OSA patients and 31 age- and body mass index- matched controls. In OSA patients, measurements were repeated after 6 months of CPAP therapy. All participants were non-smokers, without any comorbidities or systemic medication use. RESULTS: At baseline, serum VEGF levels in OSA patients were higher compared with controls (p<0.001), while IGFBP-3 levels were lower (1.41±0.56 vs. 1.61±0.38 µg/ml, p=0.039). VEGF levels correlated with apnea-hypopnea index (r=0.336, p=0.001) and oxygen desaturation index (r=0.282, p=0.007). After 6 months on CPAP treatment, VEGF levels decreased in OSA patients (p<0.001), while IGFBP-3 levels increased (p<0.001). CONCLUSION: In newly diagnosed OSA patients, serum levels of VEGF are elevated, while IGFBP-3 levels are low. After 6 months of CPAP treatment these levels change. These results may reflect an increased CV risk in untreated OSA patients, which is ameliorated after CPAP therapy.

Subjective sleep quality in lung cancer patients before and after chemotherapy.

BACKGROUND: Sleep disturbances, such as difficulty in falling asleep, maintaining sleep, poor sleep efficiency, early awakening, and excessive daytime sleepiness, are common in patients with cancer. The aim of this study was to evaluate sleep characteristics in newly diagnosed lung cancer patients before and after three months of chemotherapy treatment. METHODS: Forty-nine patients with lung cancer, without brain metastasis, were included. Anthropometric and disease characteristics were collected. Upon diagnosis and after three months, a polysomnographic examination was conducted and the patients completed the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Fatigue Severity Scale (FSS) and the Medical Research Council (MRC) dyspnoea scale. RESULTS: Before chemotherapy, the mean PSQI score was 7.1 ± 4, the FSS score was 3.92 ± 2, and the ESS score was 6.8 ± 4. The MRC score was low at 1.6 ± 1.1. A significant correlation between FSS and global PSQI was revealed (r = 0.424, P < 0.01), as well as with several of the PSQI components. After chemotherapy, no statistically significant change was observed in the PSQI (mean: 6.6 ± 4.5, t-score: 0.784, P = 0.438), or the FSS score (4.4 ± 2.2, t-score: -1.375, P = 0.177). Sleep efficiency was significantly reduced (P = 0.008), without any change in the distribution of sleep stages. CONCLUSION: The perception of sleep quality is poor among newly diagnosed lung cancer patients and is correlated with fatigue. After chemotherapy, self-reported sleep impairment is present and sleep efficiency is reduced, without significant change in sleep architecture.

Sleepiness as a marker of glucose deregulation in obstructive sleep apnea.

BACKGROUND: Excessive daytime sleepiness (EDS) is a major but not universally present feature of obstructive sleep apnea syndrome (OSAS). The latter has been associated with glucose dysmetabolism and insulin resistance. The aim of this study was to examine the role of EDS by investigating potential differences between somnolent and non-somnolent OSAS patients in glucose metabolism, insulin resistance, and levels of cardiovascular risk factors. METHODS: Included were 25 newly diagnosed otherwise healthy OSAS patients, reporting EDS (ESS ≥ 11) and 25 age- and BMI-matched, non-somnolent (ESS ≤ 10) OSAS patients, who served as controls. Fasting glucose and insulin levels, as well as homeostatic model assessment of insulin resistance (HOMA(IR)) index, levels of hs-CRP, and lipidemic profile were measured. RESULTS: The two groups did not differ in anthropometric or sleep characteristics. A significant correlation of ESS with glucose (p = 0.004), insulin (p = 0.011), and HOMA(IR) (p = 0.031) was observed. Somnolent patients had higher levels of glucose (p = 0.045), insulin (p = 0.012), and HOMA(IR) (p = 0.027). No difference was detected in other markers between the two groups. CONCLUSIONS: Daytime sleepiness in OSAS patients is associated with hyperglycemia and hyperinsulinemia. These results suggest its potential use as a surrogate marker of insulin resistance in such patients.

Low-pressure pulmonary artery aneurysm presenting with pulmonary embolism: a case series.

INTRODUCTION: Pulmonary artery aneurysm is an uncommon disorder with severe complications. The diagnosis is often difficult, since the clinical manifestations are non-specific and the treatment is controversial, as the natural history of the disease is not completely understood. CASE PRESENTATION: We describe the cases of two patients with pulmonary artery aneurysms. The first patient was a 68-year-old Caucasian man with an idiopathic low-pressure pulmonary artery aneurysm together with a pulmonary embolism. The patient preferred a conservative approach and was stable at the 10-month follow-up visit after being placed on anti-coagulant treatment. The second patient was a 66-year-old Caucasian woman with a low-pressure pulmonary artery aneurysm also presented together with a pulmonary embolism. The aneurysm was secondary to pulmonary valve stenosis. She received anti-coagulants and, after stabilization, underwent percutaneous balloon valvuloplasty. CONCLUSION: Pulmonary embolism may be the initial presentation of a low-pressure pulmonary artery aneurysm. No underlying cause for pulmonary embolism was found in either of our patients, suggesting a causal association with low-pressure pulmonary artery aneurysm.

Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.

The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which has been proved to be effective in the treatment of pulmonary arterial hypertension (PAH). This review critically addresses and highlights pharmacological aspects of bosentan such as safety, tolerability and drug interactions. The biological basis of its mode of action is demonstrated in preclinical studies on animal models of PH and an up-to-date review of clinical data is provided, supporting its practical use with a view to achieve optimal treatment goals. Major pivotal randomized placebo-control clinical trials are discussed, together with recently published data concerning its promising role as part of combination therapy. Furthermore, recent patents of novel pharmaceutical interventions in the field of PAH, expanding treatment options, are presented.

Effect of continuous positive airway pressure therapy on a large hemangioma complicated with obstructive sleep apnea syndrome: a case report.

INTRODUCTION: Hemangiomas involving the upper airway can be an uncommon cause of obstructive sleep apnea syndrome. CASE PRESENTATION: A 26-year-old Caucasian man with a known history of a large hemangioma of his head and neck presented with sleep-disordered breathing to the sleep unit of our hospital. Severe obstructive sleep apnea syndrome was revealed on polysomnography. Nasal continuous positive airway pressure was implemented effectively, reducing daytime hypersomnolence and significantly improving sleep parameters. After three years of adherent use, the patient remains in a good condition and the hemangioma is stable. CONCLUSION: Application of continuous positive airway pressure can be an effective treatment for patients with obstructive sleep apnea syndrome complicated with vascular tumors. Periodic follow-up of these patients is necessary, as little is known about the long-term effects of continuous positive airway pressure therapy.

Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role?

BACKGROUND: Obstructive Sleep Apnea Syndrome (OSAS) is associated with inflammation, but obesity may be a confounding factor. Thus, the aim of this study was to explore differences in serum levels of inflammation markers between obese individuals with or without OSAS. METHODS: Healthy individuals (n = 61) from an outpatient obesity clinic were examined by polysomnography and blood analysis, for measurement of TNF-alpha, IL-6, CRP, and fibrinogen levels. According to Apnea-Hypopnea Index (AHI), participants were divided into two BMI-matched groups: controls (AHI < 15/h, n = 23) and OSAS patients (AHI > or = 15/h, n = 38). RESULTS: OSAS patients had significantly higher TNF-alpha levels (P < .001) while no other difference in the examined inflammation markers was recorded between groups. Overall, TNF-alpha levels were correlated with neck circumference (P < .001), AHI (P = .002), and Oxygen Desaturation Index (P = .002). CONCLUSIONS: Obese OSAS patients have elevated TNF-alpha levels compared to BMI-matched controls, suggesting a role of OSAS in promoting inflammation, possibly mediated by TNF-a.

Work productivity in obstructive sleep apnea patients.

OBJECTIVES: Purpose of the study was to assess work productivity in otherwise healthy obstructive sleep apnea (OSA) patients and to explore correlations between work productivity and different characteristics of OSA patients. METHODS: Work productivity was assessed by the Endicott Work Productivity Scale (EWPS) to 115 polysomnographically confirmed OSA patients of working age, without comorbidities. Daytime sleepiness was measured by the Epworth Sleepiness Scale. RESULTS: A significant correlation was revealed between EWPS and Epworth Sleepiness Scale scores (r2 = 0.127, P < 0.001). Mean EWPS score was significantly higher in somnolent versus nonsomnolent OSA patients (31.2 +/- 16.2 vs 20.8 +/- 11, respectively; P < 0.001). No other sleep or anthropometric characteristic correlated with EWPS. CONCLUSIONS: This study demonstrates the negative effect of daytime sleepiness on work productivity of otherwise healthy OSA patients, highlighting the need of screening for OSA and sleepiness among working individuals.

Reduction of serum retinol-binding protein-4 levels in nondiabetic obstructive sleep apnea patients under continuous positive airway pressure treatment.

BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is associated with impaired glucose metabolism and insulin resistance. Retinol-binding protein-4 (RBP-4) is an adipokine, hypothesized to induce insulin resistance. OBJECTIVES: The aim of the study was to explore the association between serum RBP-4 levels and OSAS severity in nondiabetic, adherent to therapy OSAS patients and to investigate the role of continuous positive airway pressure (CPAP) in the alteration of RBP-4 levels. METHODS: OSAS patients (n = 62) without comorbidities or medication use were included. Fasting RBP-4, glucose and insulin levels, HbA(1c), homeostatic model assessment of insulin resistance index and lipid profile were measured at baseline and after 6 months of CPAP use. Patients were divided into group A (with fasting glucose levels <110 mg/dl, n = 47), and group B (with impaired fasting glucose (IFG), i.e. fasting glucose levels ≥110 mg/dl, n = 15). RESULTS: RBP-4 levels were not associated with apnea-related indices, anthropometric characteristics or markers of glycemic control, insulin resistance or lipid profile. In group A (but not in group B), a significant reduction was observed in RBP-4 (p = 0.046), HbA(1c) (p = 0.005), LDL cholesterol (p = 0.034), and high-sensitivity C-reactive protein (hs-CRP, p = 0.033) levels after 6 months of CPAP use. CONCLUSIONS: RBP-4 levels were not correlated with sleep, anthropometric characteristics, markers of glycemic control and insulin sensitivity. OSAS patients without IFG respond well to CPAP use as evidenced by the significant reduction in RBP-4, HbA(1c) and, additionally, hs-CRP and LDL- cholesterol levels. This treatment effect is not observed in patients with IFG.

Determinants of continuous positive airway pressure compliance in a group of Greek patients with obstructive sleep apnea.

OBJECTIVE: The aim of the study was to investigate the patients' characteristics that correlate with greater compliance to CPAP use. METHODS: Patients diagnosed with OSAHS and treated with CPAP, who had at least one follow-up visit in the Sleep Clinic during one year, were included in the study. Demographic data, history of symptoms, comorbidities, Body Mass Index (BMI), Epworth Sleepiness Scale questionnaire (ESS), were obtained from patients before and under CPAP use. All variables were correlated with average daily CPAP use. Objective and subjective compliance were estimated and a cut off point of 4.5h/d was used to distinguish 'more compliant' from less 'compliant' patients. RESULTS: Ninety eight patients, with a mean age (+/-SD) of 55.5 (+/-11.1) years were examined. Patients' symptoms improved after CPAP use. The objective compliance was 5.3+/-1.6h/d whereas the subjective compliance was higher. Only 25% of patients were characterized as 'more compliant'. Compliance was positively correlated in a significant way with age and female gender, and negatively correlated with neck circumference, preexisting nasal problems and minimum saturation during sleep. Patients with arterial hypertension showed a trend to better compliance. Weight gain was more frequently observed in 'less compliant' patients. CONCLUSION: To our knowledge this is the first study examining parameters of CPAP compliance in a Greek population of OSAHS patients. Age, gender and minimum saturation during sleep were related to better compliance whereas higher neck circumference and preexisting nasal problems were the parameters related to a worse adherence to treatment.

Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome.

STUDY OBJECTIVES: Several lines of evidence suggest immune system derangement in obstructive sleep apnea syndrome (OSAS) patients. However, no data exist on the long-term effect of continuous positive airway pressure (CPAP) treatment on systemic immunity. Hence, we sought to evaluate this effect on various immunological parameters in OSAS patients. DESIGN: Prospective case series. SETTING: Sleep unit of a general hospital. PATIENTS: Newly-diagnosed, nonsmoking, otherwise healthy OSAS male patients (n = 52) were evaluated on diagnosis and 6 months after CPAP treatment. According to compliance to CPAP use at 6-month follow-up, they were divided into 2 groups: group A (n = 32): good compliance (mean CPAP use > or = 4 h/night); and group B (n = 20): poor compliance (mean CPAP use < 4 h/night). INTERVENTIONS: N/A. MEASUREMENTS AND RESULTS: Blood samples were obtained at baseline and at the 6-month follow-up. Percentage and absolute count of lymphocyte subsets (by flow cytometry), serum TNF-alpha, IL-6, and uric acid levels were measured. No differences were recorded regarding the baseline anthropometric or sleep characteristics of the 2 groups. In group A, a significant decrease in the absolute count of total lymphocytes (P = 0.003), and of CD4+ cells (P = 0.001), and a decrease in TNF-alpha levels (P = 0.001) and uric acid levels (P < 0.001) was observed after CPAP application. On the contrary, no alterations occurred in any of the tested parameters in group B patients. CONCLUSIONS: The selective reduction of soluble and cellular immune response factors only in those OSAS patients who exhibited good compliance to CPAP therapy provides further evidence for an ongoing systemic immune process in OSAS.

Markers of glycemic control and insulin resistance in non-diabetic patients with Obstructive Sleep Apnea Hypopnea Syndrome: does adherence to CPAP treatment improve glycemic control?

BACKGROUND AND AIM: Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) is associated with glucose dysmetabolism and insulin resistance, therefore the amelioration of breathing disturbances during sleep can allegedly modify the levels of markers of glucose regulation and insulin resistance, such as glycated hemoglobin, fasting glucose, insulin and HOMA(IR). The aim of this study was to explore the association between these parameters and sleep characteristics in non-diabetic OSAHS patients, as well as the effect of 6 months CPAP therapy on these markers, according to adherence to CPAP treatment. METHODS: Euglycemic patients (n=56; mean age+/-SD: 46.07+/-10.67 years) with newly diagnosed OSAHS were included. Glycated hemoglobin, fasting glucose, insulin levels and HOMA(IR) were estimated at baseline and 6 months after CPAP application. According to CPAP adherence, patients were classified as follows: group 1 (mean CPAP use 4 h/night), group 2 (mean CPAP use < 4 h/night) and group 3 (refused CPAP treatment), and comparisons of levels of the examined parameters were performed. RESULTS: At baseline, average SpO(2) during sleep was negatively correlated with insulin levels and HOMA(IR) while minimum SpO(2) during sleep was also negatively correlated with insulin levels. After 6 months, only group 1 patients demonstrated a significant decrease in glycated hemoglobin (p=0.004) accompanied by a decrease in hs-CRP levels (p=0.002). No other statistically significant change was observed. CONCLUSIONS: Nighttime hypoxia can affect fasting insulin levels in non-diabetic OSAHS patients. Good adherence to long-term CPAP treatment can significantly reduce HbA(1C) levels, but has no effect on markers of insulin resistance.

Health related quality of life in Greek patients with sleep apnea-hypopnea syndrome treated with continuous positive airway pressure.

Sleep apnea-hypopnea syndrome (SAHS) causes serious symptoms and may induce patients' quality of life impairment. The aim of this study was to assess health related quality of life (HRQOL) in Greek patients with various severity SAHS before and after CPAP implementation in comparison with conservative therapy and Greek population normative data. In 180 patients (152 males, 28 females) with SAHS (apnea-hypopnea index, AHI 56 +/- 25.4/h), daytime sleepiness was assessed with the Epworth sleepiness scale (ESS) and measurements of health status were performed using the short form-36 health survey (SF-36) questionnaire and the General Health Questionnaire (GHQ-30). One hundred and thirty five patients underwent CPAP treatment and 45 were assigned to a conservative therapy. After 3 months the measurements were repeated in 105 patients under CPAP treatment and in 15 patients from the conservative group. HRQOL in all patients was lower than Greek normative data before any treatment. In patients with CPAP therapy the ESS decreased (p<0.01) and a significant improvement was observed in SF-36 dimensions (p<0.01). The improvement was more obvious in patients with severe SAHS (p<0.05) than in patients with moderate disease severity. In the majority of patients (60.9%), GHQ-30 score was high and it was negatively related to some SF-36 dimensions and positively to ESS. In patients under conservative therapy, no significant changes were observed in any measure. HRQOL in patients with SAHS at the time of diagnosis was low and reached general population levels in patients treated with CPAP. The improvement was greater in those with severe syndrome.

Noise levels in Greek hospitals.

UNLABELLED: High noise levels have been recognized as a serious problem in hospital environments during both night- and daytime, and have been associated with a negative impact on patients' health status. The aim of this study was to measure and detect differences in noise levels between an ICU and a pulmonary ward in two general hospitals in Greece. METHODS: Noise measurements were recorded in one-hour intervals using the Cirrus CR: 245/R2 Environmental Noise Analyzer in a 30-bed pulmonary ward and in a 16-bed general ICU for seven consecutive days. RESULTS: Noise levels detected in the ward were significantly lower than those detected in the ICU (52.6 +/- 8.2 dB vs 59 +/- 2.2 dB, P Conclusion: Noise levels measured in the ward and in the ICU were high, significantly exceeding the highest permitted values for hospitals. The latter was more obviously recorded in the ICU.

Quality of life and social-economic characteristics of greek male patients on long-term oxygen therapy.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) profoundly impacts patients' functional status, especially in the advanced stages, when long-term oxygen therapy (LTOT) is implemented. OBJECTIVE: To determine the health-related quality of life (HRQOL) in patients with COPD and using LTOT, and assess the relationship of socioeconomic characteristics and pulmonary function test results to HRQOL scores. METHODS: We studied a group of 85 patients with COPD and hypoxemia who were on LTOT, and a control group of 48 patients with stable COPD but without hypoxemia. All subjects were asked to rate their dyspnea on the Modified Medical Research Council dyspnea scale, and to take the Medical Outcomes Study Short Form (SF-36), the General Health Questionnaire (30 questions), and a questionnaire (which we developed for this study) to measure their independence in activities of daily living (ADL). We also conducted pulmonary function tests and arterial blood gas analyses, and recorded socioeconomic characteristics. RESULTS: The subjects' socioeconomic status was moderate to low. HRQOL was impaired in patients on LTOT, especially in the physical function domain, and most of the examined dimensions correlated with the severity of dyspnea and psychological status. There was a significant association between ADL score and SF-36 score in the vitality and physical domains, but there was no significant association between HRQOL score and spirometry or blood gas values. CONCLUSIONS: HRQOL in patients with COPD and on LTOT is low and is influenced by dyspnea, mental status, and incapacity, rather than by physiological variables. We recommend a multidimensional therapeutic approach that targets symptom-control and ADL support to improve the patient's overall HRQOL.